| Multiple Sclerosis |
1 |
1 |
| Monoclonal Antibody |
0 |
0.69 |
| Jobs |
0 |
0.42 |
| Multiple Sclerosis Relapse |
0 |
0.42 |
| Biologic Therapy |
0 |
0.36 |
| Antineoplastic Drug |
0 |
0.28 |
| Clinical Research |
0 |
0.28 |
| Intravenous |
0 |
0.28 |
| Stiff Person Syndrome |
0 |
0.28 |
| Immunoglobulin G (IgG) |
0 |
0.24 |
| Healthcare and Medical Technology |
0 |
0.22 |
| Serum Immunoglobulin A (IgA) |
0 |
0.2 |
| Adherence |
0 |
0.14 |
| Brain |
0 |
0.14 |
| Disability |
0 |
0.14 |
| Immunoglobulin A (IgA) |
0 |
0.14 |
| Match |
0 |
0.14 |
| Medical Innovations |
0 |
0.14 |
| Primary Progressive Multiple Sclerosis |
0 |
0.14 |
| Remission |
0 |
0.14 |
| Shared Decision-Making |
0 |
0.14 |